GlassScriptPhysician profile
Lingappa Amarchand
NPI 1346276631
$2,733.00
in general payments reported to CMS, 2019-2025
22 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $515 · 2021: $508 · 2022: $247 · 2023: $71.16 · 2024: $260 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $602.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $370.49 | 2019-2023 | Xarelto |
| Lundbeck LLC | $246.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.34 | 2019-2025 | Jardiance |
| Amgen INC. | $176.63 | 2019-2021 | |
| Boston Scientific Corporation | $170.46 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.07 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $152.18 | 2021-2025 | Verquvo |
| Pfizer INC. | $149.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.22 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $77.11 | 2020-2025 | |
| Elutia, INC. | $65.27 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $46.97 | 2019-2020 | |
| Abbott Laboratories | $39.03 | 2021 | |
| Novo Nordisk INC | $35.54 | 2021-2025 | Ozempic |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $33.27 | 2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $30.04 | 2020 | |
| Esperion Therapeutics, INC. | $24.35 | 2020-2021 | |
| Braemar Manufacturing, LLC | $18.41 | 2019 | |
| Philips North America LLC | $15.64 | 2025 | Ecc Solutions |
| Actelion Pharmaceuticals US, INC. | $15.62 | 2023 | Uptravi, Opsumit |
| Arbor Pharmaceuticals, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lingappa Amarchand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.